HK1189350A - The use of extract of asplenium nidus l. - Google Patents

Description

Extract of common perilla and its use

Technical Field

The invention relates to a plant extract and application thereof, in particular to a common perilla extract and application thereof in improving prostate gland diseases.

Background

The Prostate gland, also known as the Prostate gland (Prostate), is located at the bladder outlet, surrounds the urethra, and is one of the genital organs unique to men.

Benign Prostatic Hyperplasia (BPH) is a common Benign tumor in men, and the pathogenesis of the Benign Prostatic Hyperplasia is still unknown in men over fifty years old, and is presumed to be related to age increase and hormone secretion. Generally, the enlargement of the prostate directly compresses the urethra, resulting in excessive contraction of the urethra and increased internal pressure, which may cause urination disorders, such as urinary tract interruption, frequent urination, urine leakage and incomplete sensation of urination, and in severe cases, may cause uremia or renal failure. Although benign prostate hyperplasia does not increase the risk of prostate cancer, benign prostate hyperplasia is similar to early symptoms of prostate cancer and is not easy to distinguish, which may lead to correct diagnosis of prostate cancer, delay diagnosis or affect mood of patients.

The existing benign prostatic hyperplasia treatment can depend on surgical resection or medicines, the prognosis period of the surgical resection is long and the risk is slightly high, so that medical medicine is still the main treatment means, the common existing medicines comprise alpha adrenergic blockers (alpha), such as Minipress, Dibenyline, Hytrin, Doxaben, Xatral and the like, and hormone inhibitors, however, the two medicines have the possibility of derivative side effects, and can cause problems of postural hypotension, urinary incontinence, nasal obstruction, fatigue, sexual dysfunction and the like, and the common medicines can cause serious medical injury and cause intolerable decoction of patients when being taken together with other medicines (such as cold medicines, cardiovascular disease medicines or blood pressure reducing medicines). In addition, it has been shown that long-term administration of the conventional drugs increases the risk of cancer (severe prostate and breast cancer), especially in snow-covered patients.

In recent years, the concept of natural regression and health preservation has been developed in the countries in the european and american countries, so that Traditional Medicine (TM) or assisted alternative medicine (CAM) is gradually popular, and thus, the development of traditional Chinese herbal medicine and natural plant related to prostate gland diseases has been seriously considered, and there are reports that natural plants or components thereof, such as medical lycopene, pumpkin seeds, Saw palms (sau Palmetto), african prunus salicina (Pygeum Africana) and lutein, have obvious curative effects on male prostate gland health care, however, the natural plants have many problems that the curative effects are not obvious (the curative effects of lycopene and pumpkin seeds on prostate gland diseases are limited), or are limited by the origin or extraction efficiency of raw materials, such as Saw palms and african prunus salicina are only produced in africa or along the atlantic world, the raw materials are not easy to obtain, and the extraction efficiency varies with the extracted parts, thus reducing the level of application; furthermore, some natural plants may have the possibility of inducing side effects, such as stomach discomfort, nausea, constipation or diarrhea (recorded in network data: http:// liaozhai. pujiaa. com/thread-500003-1.html), in saw palms, which may not cause serious sequelae, but may eventually cause discomfort to the user and make it difficult to obtain the identity of the same.

Therefore, if a plant medicine with significant curative effect on prostate hypertrophy can be further found, the development of application of the plant medicine to treatment and prevention medicines is inevitably expected by various circles, so as to effectively improve the problem of prostate gland in human beings.

Shan su (Asplenium nidus L.) belongs to fern, is a perennial large edible plant, is originally produced in Taiwan and southeast Asia, is usually produced on the humid trunk or the fine cracks of rocks, and is cultivated in large quantities in Taiwan all places in the field of flat land agriculture. According to the traditional medical record, the mountain perilla is rich in various nutritional ingredients and dietary fibers, the tender leaves of the mountain perilla are subspecies food materials and are suitable for cooking, the safety is high after long-term eating, the tender leaves of the mountain perilla have the effects of preventing hypertension, diabetes and the like, the vegetable is a healthy vegetable for preventing constipation and colorectal cancer of modern people, and related reports and applications of the vegetable in improving prostate gland diseases are not found.

Disclosure of Invention

The invention mainly aims to provide a common perilla extract which contains natural active ingredients for inhibiting masculine and can effectively improve diseases related to male prostate gland.

The invention provides a common perilla extract which has a remarkable regulation function on hormone receptor regulation, is convenient to obtain and separate and can be applied to development of pharmaceutical compositions or health-care foods for improving male prostate gland.

The invention also aims to provide the application of the common perilla extract in improving male prostate diseases, and the common perilla extract is used as an active ingredient and is applied to development of pharmaceutical compositions or health-care foods for treating or preventing the male prostate diseases.

In order to achieve the above object, the present invention provides a method and a device for achieving the above object, comprising:

a Stachys extract comprises pyropheophorbide-alpha-methyl ester, pheophorbide-alpha-methyl ester, 1-linoleic acid-3-linolenic acid-glyceride, 1-linolenic acid-2, 3-dipalmitic acid-glyceride, and 1, 3-dipalmitic acid-glyceride.

The perilla frutescens extract is prepared by a method comprising the following steps: a solvent extraction step, wherein an extraction solvent is used for extracting a stachys sieboldii sample, the weight-volume ratio (w/v, g/mL) of the stachys sieboldii sample and the extraction solvent is 50-60 mg/mL, and an extract is recovered; and a column chromatography step, namely performing chromatographic separation treatment on the extract by using water and ethanol as mobile phases to obtain a plurality of distinguishes, washing the distinguishes sequentially and numbering the distinguishes as a section a to a section i, and selecting the section c to perform reduced pressure concentration and freeze drying to obtain the common perilla extract.

The extraction of the perilla frutescens of the invention is obtained by selecting the section b, concentrating under reduced pressure and freeze-drying in the step of column chromatography.

The extraction of the perilla frutescens is obtained by selecting the section d, concentrating under reduced pressure, and freeze-drying in the step of column chromatography.

The perilla frutescens extract of the invention is prepared by extracting 95% ethanol as an extraction solvent in the solvent extraction step.

The perilla frutescens extract of the invention is prepared by extracting perilla frutescens with water.

The method further comprises a step of selecting the root of the whole plant of the perilla frutescens as the perilla frutescens sample.

And the application of the common perilla extract, namely applying the common perilla extract as an active substance to preparing a pharmaceutical composition for treating prostate gland diseases.

The application of the perilla frutescens extract is to use the perilla frutescens extract as an active substance to prepare health-care food for treating prostate diseases.

The application of the common perilla extract in treating prostate diseases comprises prostate hypertrophy, prostate cancer and prostate inflammation.

The use of the perilla frutescens extract of the invention is characterized in that the perilla frutescens extract is orally administered to a biological subject.

The usage of the perilla frutescens extract of the present invention, wherein the administration amount of the perilla frutescens extract is 10 to 50 mg per unit weight (kg) of the biological subject per day, preferably 50 mg per unit weight (kg) of the biological subject per day.

The extract of perilla frutescens of the present invention has natural active ingredients that inhibit androgenic hormones, and thus, can effectively improve diseases caused by the imbalance of hormone receptors, particularly diseases related to male prostate gland, without causing side effects. The perilla frutescens extract can be prepared industrially or through a supercritical extraction step, and is applied to the development of pharmaceutical compositions or health-care foods for treating or preventing male prostate diseases so as to improve the problem of male prostate diseases, and the effect of the invention is achieved.

Drawings

FIG. 1 is a chemical structural diagram of pyropheophorbide-alpha methyl ester according to the present invention.

FIG. 2 is a chemical structural diagram of methyl pheophorbide-a according to the present invention.

FIG. 3 is a chemical structural diagram of 1-linoleic acid-3-linolenic acid-glyceride of the present invention.

Fig. 4 is a chemical structure diagram of the 1-linolenic acid-2, 3-dipalmitic glyceride of the present invention.

Fig. 5 is a chemical structure diagram of the 1, 3-dipalmitic-glyceride of the present invention.

FIG. 6 is a flow chart of the extraction method of the extract of Stachys sieboldii of the present invention.

FIG. 7 is a sectional view of the extraction of the extract of the plant of the present invention.

FIG. 8 is a flow chart of another extraction method of the extract of Stachys sieboldii of the present invention.

Fig. 9 is a graph showing the inhibitory effect of the extract of stachys sieboldii of the present invention on androgens.

Fig. 10 is a graph showing the inhibitory effect of the extract of stachys sieboldii of the present invention on androgens.

FIG. 11 is a schematic representation of the inhibitory effect of the extract of Stachys japonica according to the present invention on prostate-basal myofibroblasts.

Fig. 12 is a schematic diagram of the inhibitory effect of the stachys sieboldii extract on prostate cancer cell lines.

FIG. 13 is a graph showing the relationship between the dose of the extract of Saussureae to the ability to suppress prostate cancer cells.

FIG. 14a is a graph showing that the extract of Saussurea japonica of the present invention decreases the prostate gland index in mice.

FIG. 14b is a schematic diagram of the extract of Stachys japonica of the present invention for improving the urine output of mice.

Fig. 14c is a schematic illustration of the reduction of water intake in mice with the extract of tassel herbacea of the present invention.

Fig. 15 is a schematic diagram of the pathological features of the extract of common perilla in inhibiting prostate hypertrophy.

(present invention)

S1 solvent extraction step

S2 column chromatography step

And S3 selecting.

Detailed Description

In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below:

referring to FIGS. 1 to 5, the extract of Stachys sieboldii of the present invention comprises pyropheophorbide a methyl ester (C) shown in FIG. 1₃₄H₃₆N₄O-, 5% of the total weight of the stachys sieboldii extract), the pheophorbide a methyl ester shown in fig. 2 (pheophorbide a methyl ester; c₃₅H₃₆N₄O₅3.4% of the total weight of the stachys sieboldii extract), 1-linoleic acid-3-linolenic acid-glyceride (1-linoloyl-3-linoloyl-glycerol; c₃₉H₆₆O₅2.9% of the total weight of the behenic extract), 1-linolenic acid-2, 3-dipalmitoyl-glyceride (1-linoleoyl-2, 3-dipalmitoyl-rac-glycol) as shown in fig. 4; c₅₃H₉₈O₆5.4% of the total weight of the behenic extract), and 1, 3-dipalmitoyl-sn-glycol as shown in fig. 5; c₃₅H₆₈O₅7.3% of the total weight of the perilla frutescens extract). The extract can effectively inhibit androgen secretion and prevent inflammation, thereby improving male prostate gland diseases.

Referring to fig. 6, the perilla frutescens extract of the present invention is obtained by an extraction method comprising the following steps: a solvent extraction step S1 and a column chromatography step S2. The solvent extraction step S1 is to perform an extraction treatment on a tassel sample by using 95% ethanol or water as an extraction solvent to obtain an extract, wherein the weight-to-volume ratio (w/v, g/mL) of the tassel sample to the extraction solvent is 50 to 60 mg/mL.

The column chromatography step S2 is to perform chromatographic separation of the extract with a silica gel column as a stationary phase and water and ethanol as mobile phases to obtain a plurality of partitions, which are numbered from section a to section i, and selected from sections b, c, d or a combination thereof according to the sequence of washing, and then the stachys sieboldii extract of the present invention is obtained after vacuum concentration and freeze drying.

More specifically, the column chromatography step S2 is to perform a chromatographic separation process on the extract by using an automated medium-sized column liquid chromatography (Flash LC), preferably using a C18 protein purification reaction phase column (reverse phase column) as a stationary phase to increase the extraction rate, sequentially performing elution by using mobile phases with different ratios, and collecting the elution solutions in stages to obtain a plurality of fractions, as shown in fig. 7. The plurality of distinguishes are respectively segments a to i according to the sequence of extraction, and the extraction segments b, c and d or the composition thereof are subjected to reduced pressure concentration and freeze drying to obtain the perilla frutescens extract. The mobile phase of the invention is a linear gradient formed by mixing ethanol and water, wherein the mixing of the ethanol and the water is promoted from 70% ethanol to 100% ethanol (V/V).

Referring to fig. 8, before the solvent extraction step S1, a picking step S3 is preferably performed to pick the root of the whole plant of tsuwooshua as the tsuwooshan sample to obtain a tsuwooshan extract with high active ingredients, wherein the tsuwooshan sample can be selected from tsuwooshan (aspenium ariquuum Makino; also called bird ' S fern and nest fern) or taiwan tsuwooshan (aspenium nidus Linn; also called taiwan bird ' S fern and taiwan bird ' S fern), preferably the whole plant of taiwan perilla frutescens (aspenium nidus Linn) contains the root, the distribution and species area of taiwan perilla frutescens in taiwan is wide, the taiwan perilla frutescens extract can be produced all the year round, the preparation and raw material acquisition of the tsuwooshan extract are more beneficial, and the problem of the plant diseases and insect pests of the tsuwooshan extract is mostly clean without agricultural pollution, and the problem of the plant diseases and insect pests or pesticide pollution can be improved.

The Stachys extract of the present invention is verified by scientific verification to have effective components for resisting inflammation and inhibiting androgenism, including pyropheophorbide-alpha methyl ester, pheophorbide-alpha methyl ester, 1-linoleic acid-3-linolenic acid-glyceride, 1-linolenic acid-2, 3-dipalmitic acid-glyceride and 1, 3-dipalmitic acid-glyceride, so that the Stachys extract can be controlled to exert an expected function on a hormone receptor, and further improve diseases caused by the imbalance of the hormone receptor, such as male prostate diseases (including benign prostate hypertrophy, prostate cancer and prostate inflammation), male and female urinary incontinence, female male baldness, female climacteric disorder, etc.

Moreover, the stachys sieboldii extract is convenient for extraction and separation and has the potential of being applied to the development of new drugs. The common perilla extract is used as an active ingredient and is applied to the development of pharmaceutical compositions or health-care foods for treating or preventing the diseases, in particular to the pharmaceutical compositions or the health-care foods for improving the male prostate diseases, thereby improving the health problems of the Chinese people. The perilla frutescens extract can be used for developing components of related medicines or health-care food, or combined with a compound by matching with pharmaceutically acceptable carriers, excipients, salts or other nutritional components. In addition, the perilla frutescens extract can be further processed to prepare any dosage form suitable for oral administration, such as troche, capsule, powder, pill, liquid or leavening, or combined with other food or beverage to prepare a food form more suitable for taking.

To confirm that the extract of the present invention has the effect of inhibiting androgenic activities, the following experiments were conducted, but the application thereof is not limited thereto:

in this experiment, the extraction step S3, the solvent extraction step S1, and the column chromatography step S2 were performed in sequence according to the above-mentioned extraction method, and 95% ethanol was used as an extraction solvent to extract the tsunami sample, and then the automated medium-sized column liquid chromatograph was used to separate nine sections (a to i) obtained by using a C18 protein purification reaction phase column. Referring to FIG. 9 and FIG. 10, the nine segments were cultured with prostate cancer cells 22Rv/103E alone or with prostate cancer cells 22Rv/103E and prostate-basement myofibroblasts (stromalminofibroblast) -WPMY-1, respectively, and then the inhibitory activity of the nine segments on androgens was determined.

The results show that the sections b, c and d have significant inhibitory effect on the androgenic hormone when cultured with prostate cancer cells 22Rv/103E alone (as shown in fig. 9) or cultured with prostate cancer cells 22Rv/103E103E and prostate-basic myofibroblasts (stromal myofibroblasts) -WPMY-1 together (as shown in fig. 10), and the inhibitory effect is proportional to the dose of the sections b, c and d.

Referring to fig. 11 and 12, the effects of the nine segments on the growth of prostate-based myofibroblasts-WPMY-1 and prostate cancer cell line LNCaP are shown. The nine sections are respectively cultured with the prostate basic layer myofibroblast-WPMY-1 and the prostate cancer cell strain-LNCaP for 48 hours, the cultured cells are stained by an SRB stain, and then the cell activities of the cells are respectively measured. The results show that the sections b, c and d can indeed inhibit the growth of the prostate-based myofibroblast-WPMY-1 and the prostate cancer cell line-LNCaP, and that the inhibition is substantial to the doses of the sections b, c and d.

Please refer to FIG. 13, which shows the effect of the combination of segments b, c and d on the growth of prostate-based myofibroblasts-WPMY-1 (1) and prostate cancer cell line LNCaP (2). The inhibition ability of the composition against the prostate basal myofibroblast-WPMY-1 and the prostate cancer cell line-LNCaP was determined by colony growth assay (colony formation assay) at different doses, and the results showed that the dose of the composition was positively correlated with the inhibition ability of the composition against prostate cancer cell growth, and that higher doses (e.g., 100 μ g/mL) of the composition caused more prostate cancer cell death. The composition has half inhibitory dose (IC) on prostate primary myofibroblast-WPMY-1 and prostate cancer cell strain-LNCaP₅₀Value) was 11.63. mu.g/mL and 13.19. mu.g/mL, respectively.

In addition, in order to confirm that the perilla frutescens extract of the present invention can effectively improve the symptom of prostate hypertrophy of mice, the following tests are performed, but the application scope is not limited thereto:

a C57BL/6Jnar1 male mouse (purchased from national animal center) is selected for the test, the mouse is bred in an SPF animal house of the research center of agriculture and biotechnology of the research center of the research institute of the Chinese institute of technology, the breeding environment is 22 ℃, and the illumination time and the dark time are 12 hours respectively.

In the experiment, phenylephrine (PE for short) is injected subcutaneously, 15 mg of the phenylephrine is administered to each kilogram of body weight, so as to activate alpha 1-adrenergic receptors, and further induce mice to generate prostate hypertrophy (the induction period is five times of the phenylephrine injections per week and five weeks of the continuous injections); and at the same time, the common perilla herb extract of the invention is orally fed with different dosages, and the prostate index (PI for short), the urination state and the drinking state of the mouse are observed and recorded in fig. 14a, 14b and 14 c; after sacrificing the mice, the prostate was sectioned and stained, and the results are shown in fig. 15.

Referring to fig. 14a, compared to the control group, the prostate index of the mice (PE group) administered with phenylephrine was significantly increased, indicating that the mice developed enlargement of the inside of the prostate, and the mice had both reduced urination and reduced water intake; meanwhile, feeding the extract of the perilla frutescens (ANE group, without the step of column chromatography, with the dosage of 100 mg per kg of body weight of mice per day) or the extract of the perilla frutescens of the present invention (Lo group, with the dosage of 10 mg per kg of body weight of mice per day; or Hi group, with the dosage of 50 mg per kg of body weight of mice per day) can effectively alleviate the change of the prostate-taking index of the mice, and can also alleviate the problems of the reduction of urination and the increase of water intake of the mice (p < 0.01, please refer to fig. 14b and 14 c), wherein the effect of feeding 50 mg of the extract of the perilla frutescens of the present invention per kg of body weight of mice per day (Hi group) is the best. Therefore, the common perilla extract can effectively relieve the prostate hypertrophy phenomenon of organisms.

Then, after the five groups of mice (control group, PE group, ANE group, Lo group and Hi group) were sacrificed, the prostate was sectioned and Hematoxylin-eosin staining (H & E staining) was performed, and compared to the control group, the mice (PE group) administered with phenylephrine could observe epithelial cell proliferation, so that the area of the urinary tract cavity of the PE group mice was significantly reduced, indicating that the secretory glands of the PE group mice were compressed (as shown in ii of fig. 15), and at the same time, either the kefir extract (ANE group) or the kefir extract (Lo group or Hi group) of the present invention could effectively alleviate the epithelial cell proliferation (as shown in iii, iv and v of fig. 15).

In addition, referring to vii to xi in fig. 15, the distribution of collagen in each section is observed by the mein's trichrome staining method (Masson's trichrome staining), the distribution of collagen in the control group is wide (as shown in vii in fig. 15, the blue area indicated by yellow arrow is collagen), the distribution of reticular fibers in the prostate matrix (as shown by orange arrow) is observed, but the section of the PE group mouse is difficult to observe (as shown in viii in fig. 15), and the above phenomenon can be effectively recovered by feeding the tsunami extract (Hi group) of the present invention (as shown in ix in fig. 15).

Therefore, the common perilla extract can effectively relieve the prostate hypertrophy phenomenon caused by the phenylephrine, increase the urine output of mice, and relieve the pathological characteristics caused by the prostate hypertrophy, can be used as an active substance for improving the prostate problem of males, and is applied to preparation of a pharmaceutical composition or a health-care food for treating the prostate diseases.

The practical application of the extract of the invention is shown in the following examples, but the application is not limited to these examples:

in this embodiment, the extraction step S3, the solvent extraction step S1, and the column chromatography step S2 are sequentially performed according to the above-mentioned extraction method to obtain the stachys sieboldii extract. Referring to table 1, the extract of tassel fruticosa is provided for 88 prostate gland disease patients of different ages, which can improve urination of patients in two to four weeks on average without causing any side effect, and is helpful for treating prostate hypertrophy, prostate inflammation or prostate cancer.

One of the symptoms of the hyperplasia of prostate is frequent urination and nocturia, and the perilla frutescens extract can reduce the frequency of the frequent urination and the nocturia to be the same as that of normal people. The former 88 patients were analyzed before and after the trial according to the International Prostate Symptom Score (I-PSS), and the Score of progress averaged at least about 20 to 30 points over 2 to 4 weeks, which is much higher than the average 2 to 3 points of the commercially available nutritional supplement products, and the average 14 points of the medication.

TABLE 1 use results of 88 patients with prostate disease

^aPost-operative adhesions of the urethra are not the post-operative, exclusive signs of prostate hypertrophy or prostate cancer. Even after severe cases, the patients are delayed for several months, and usually are relieved by using alpha-receptor blockers. However, the perilla frutescens extract has the effects of quick acting, lasting action and the like, and can be used for improving the urethral adhesion.

As described above, the perilla extract of the present invention has natural active ingredients for anti-inflammation and androgen suppression, and thus, can effectively improve diseases caused by hormone receptor imbalance, particularly male prostate-related diseases, without causing side effects. The perilla frutescens extract can be prepared industrially or through a supercritical extraction step, and is applied to the development of pharmaceutical compositions or health-care foods for treating or preventing male prostate diseases so as to improve the problem of male prostate diseases, and the effect of the invention is achieved.

Claims (15)

1. A Stachys extract comprising:

pyropheophorbide-alpha methyl ester;

pheophorbide-alpha methyl ester;

1-linoleic acid-3-linolenic acid-glyceride;

1-linolenic acid-2, 3-dipalmitic-glyceride; and

1, 3-dipalmitic-glyceride.

2. The extract of perilla frutescens as claimed in claim 1, wherein the extract is prepared by a method comprising the steps of:

a solvent extraction step of subjecting a perilla frutescens sample to extraction treatment using an extraction solvent so that the weight-to-volume ratio (w/v, g/ml) of the perilla frutescens sample to the extraction solvent is 50 to 60mg/ml, and recovering an extract; and

a column chromatography step, using a linear gradient formed by mixing ethanol and water as a mobile phase to perform chromatography separation treatment on the extract, wherein the mixing of ethanol and water is increased from 70% ethanol to 100% ethanol (V/V) to obtain a plurality of partitions, the partitions are numbered as sections a to i according to the flushing sequence, and the section c is selected to be subjected to reduced pressure concentration and freeze drying to obtain the perilla frutescens extract.

3. The extract of perilla frutescens as claimed in claim 2, wherein the step of column chromatography comprises extracting the section b, concentrating under reduced pressure, and freeze-drying to obtain the extract of perilla frutescens.

4. The extract of perilla frutescens as claimed in claim 2, wherein the step of column chromatography comprises extracting the section d, concentrating under reduced pressure, and freeze-drying to obtain the extract of perilla frutescens.

5. The extract of perilla frutescens as claimed in claim 2, wherein the solvent of the solvent extraction step is 95% ethanol.

6. The extract of perilla frutescens as claimed in claim 2, wherein the extraction solvent of the solvent extraction step is water.

7. The extract of claim 2, further comprising a step of selecting the root-containing part of the whole plant of Sowthorn flower as the Sowthorn sample.

8. The extract of perilla frutescens as claimed in claim 7, wherein the selecting step selects the whole plant of perilla frutescens (Asplenium antimuum Makino) containing root as the sample of perilla frutescens.

9. The extract of perilla frutescens as claimed in claim 7, wherein the selecting step selects the whole plant of perilla frutescens (Asplenium nidus Linn) containing root as the sample of perilla frutescens.

10. Use of the extract of perilla frutescens as claimed in claim 1, 2,3 or 4 as an active substance for the preparation of a pharmaceutical composition for the treatment of prostate diseases.

11. Use of the extract of tassel virginiana as claimed in claim 1, 2,3 or 4 as an active substance in the preparation of a health food for the treatment of prostate diseases.

12. The use of the extract of perilla frutescens as claimed in claim 10 or 11, wherein the prostate diseases include prostate hypertrophy, prostate cancer and prostate inflammation.

13. The use of the extract of perilla frutescens as claimed in claim 10 or 11, wherein the extract of perilla frutescens is orally administered to a biological subject.

14. The use of the extract of alpine rush as claimed in claim 10 or 11, wherein the amount of alpine rush extract administered is 10 to 50 mg per unit weight (kg) of the subject per day.

15. The use of the extract of perilla frutescens as claimed in claim 14, wherein the amount of perilla frutescens extract administered is 50 mg per unit weight (kg) of the subject per day.